RAS testing in metastatic colorectal cancer: advances in Europe

• Published in: Virchows Archiv : an international journal of pathology Vol. 468; no. 4; pp. 383 - 396
• Main Authors: Van Krieken, J Han JM, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Normanno, Nicola, Patterson, Scott D., Jung, Andreas
• Format: Journal Article Book Review
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2016; Springer Nature B.V
• Subjects: Biomarkers, Tumor - genetics; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Europe; Gene Expression Profiling - methods; Humans; Medicine; Medicine & Public Health; Mutation; Pathology; Patient Selection; Precision Medicine - methods; Quality assurance; ras Proteins - genetics; Review and Perspectives; Review and s; Europe; Biomarkers; Sequencing; Colorectal cancer; Quality assurance programs; RAS
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-015-1876-7

Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients with metastatic colorectal cancer. Recent studies have shown that broader RAS testing ( KRAS and NRAS ) is needed to select patients for treatment. While Sanger sequencing is still used, approaches based on various methodologies are available. Few CE-approved kits, however, detect the full spectrum of RAS mutations. More recently, “next-generation” sequencing has been developed for research use, including parallel semiconductor sequencing and reversible termination. These techniques have high technical sensitivities for detecting mutations, although the ideal threshold is currently unknown. Finally, liquid biopsy has the potential to become an additional tool to assess tumor-derived DNA. For accurate and timely RAS testing, appropriate sampling and prompt delivery of material is critical. Processes to ensure efficient turnaround from sample request to RAS evaluation must be implemented so that patients receive the most appropriate treatment. Given the variety of methodologies, external quality assurance programs are important to ensure a high standard of RAS testing. Here, we review technical and practical aspects of RAS testing for pathologists working with metastatic colorectal cancer tumor samples. The extension of markers from KRAS to RAS testing is the new paradigm for biomarker testing in colorectal cancer.